) third-quarter 2013 adjusted earnings per share of 40 cents
missed the Zacks Consensus Estimate by a penny and was lower than
the year-ago earnings of 43 cents by 7%. However, earnings were
within the company's guidance of 37-42 cents. Adjusted earnings
per share would have come in at 43 cents excluding the medical
devices excise tax (MDET).
The medical technologies and surgical devices company's reported
net income dropped to $5.7 million or 20 cents per share from
$9.3 million or 32 cents in the year-ago quarter. The decline was
mainly driven by special charges and a 3-cent hit from the MDET.
Revenues decreased 1.4% year over year (down 0.4% at constant
exchange rate or CER) to $179.3 million, missing the Zacks
Consensus Estimate of $187 million. It also failed to meet the
company's revenue guidance of $184-$189 million. The downfall
resulted from weaker sales of capital equipment, specifically in
the surgical visualization and powered instrument businesses.
On a geographic basis, revenues in the U.S. were down 3.6% to $89
million, while international revenues inched up 0.8% (2.9% at
CER) to $90 million. We also note that single-use products sales
(81% of total sales) increased 2.4% at CER to $145.9 million,
while capital offerings (19%) dropped 11.1% at CER to $33.4
million in the quarter.
Adjusted gross margin (excluding restructuring expenses)
increased 30 basis points (bps) to 55.1% in the third quarter of
2013 from 54.8% in same quarter of 2012. Sequentially, adjusted
gross margin increased 90 bps. However, on a reported basis,
gross margin declined 60 bps to 53.2% from 53.8% in the
prior-year period. The fall in margin was attributed to increased
expenses associated with the termination of the company's ECOM
product line and facility consolidation expenses.
Selling and administrative charges decreased 0.8% to $73.5
million, while research and development expenses increased 0.4%
to $7.1 million in the quarter. On an adjusted basis, operating
margin dipped 10 bps to 10.1%. However, on a reported basis,
operating margin was 4.9% in the third quarter compared with 7.8%
in the year-ago quarter.
This is mainly on account of higher restructuring expenses and
the MDET. Management has also decided to discontinue its ECOM
product line and endotracheal measure cardiac output, which it
intends to sell off to a third party.
ALIGN TECH INC (ALGN): Free Stock Analysis
CARDINAL HEALTH (CAH): Free Stock Analysis
CONMED CORP (CNMD): Free Stock Analysis
MERIT MEDICAL (MMSI): Free Stock Analysis
To read this article on Zacks.com click here.
product line includes CONMED's sports medicine group and power
surgical instruments. Revenues from this product line inched down
0.6% (up 0.8% at CER) to $95.6 million.
CONMED has combined its electrosurgery, endosurgery, endoscopic
technologies and patient care into the
categorization. Revenues from this product group increased 1.0%
(1.7% at CER) to $69.9 million.
However, revenues from the
line, which includes 2D and 3D imaging devices, surprisingly
plunged 16.4% both in terms of reported and CER to $13.8 million
in the quarter. This reflects a marked disappointment from the
sales growth of 25.2% recorded in the second quarter of 2013.
CONMED exited the third quarter with cash and cash equivalents of
$49.3 million, significantly higher than $23.7 million at the end
of 2012. Long-term debt (inclusive of current portion) increased
39.0% to $225.1 million from $161.9 million as of Dec 31, 2012.
For the nine months ending Sep 30, 2013, operating cash flow
declined 12.6% to $53.6 million versus $61.3 million in the
comparable year-ago period. The company repurchased 1.4 million
shares for $44.7 million in the first nine months of 2013, all of
which were repurchased as of June 30, 2013.
For the fourth quarter, revenues are expected in the band of
$195-$200 million. This translated into lower revenue guidance of
$754-$759 million for the full year-2013 compared with the
earlier guided range of $770-$775 million. The current Zacks
Consensus Estimate for earnings for the fourth quarter and full
year 2013 is pegged at $203 million and $771 million,
Management reduced its outlook in anticipation of a difficult
capital spending environment in the U.S. as well as in other
nations. However, based on solid sales of single-use surgical
devices in the first nine months of 2013, CONMED is confident
that surgical procedures will continue to improve globally.
CNMD expects fourth-quarter 2013 adjusted earnings in the range
of 47 cents to 52 cents. Hence, the forecast for 2013 adjusted
earnings per share has been reduced to $1.75-$1.80 from the
earlier guidance of $1.80-$1.85. The current Zacks Consensus
Estimate for earnings for the fourth quarter and full year 2013
is pegged at $203 million and $771 million, respectively.
We are disappointed with CONMED's third-quarter results, which
missed the Zacks Consensus Estimate on both fronts. The company's
stock price fell almost 3% to $36.61 on Oct 24, following the
earnings release. The persistent dismal macroeconomic conditions
along with poor capital spending loom as causes of concern.
Moreover, the company operates in a highly competitive orthopedic
surgery market against much larger and more technically competent
CONMED's tempered guidance failed to impress us as well. However,
the only positive factor we took note of was improving surgical
procedure growth, which led to higher sales of single-use
CONMED carries a Zacks Rank #3 (Hold). While we choose to remain
on the sidelines regarding CNMD, other companies like
Align Technology Inc.
Cardinal Health, Inc.
Merit Medical Systems, Inc.
) are expected to do well in the medical/dental supplies
industry. All these stocks carry a Zacks Rank #1 (Strong